Analyst Bullish on Cynosure (CYNO) Acquisition of PMTI (PMTI)

Article Related Press Releases (1) Related Articles (2) Stock Quotes (2) Comments (0)

Cynosure, Inc. (Nasdaq: CYNO) and Palomar Medical Technologies, Inc. (Nasdaq: PMTI) today announced that they have signed a definitive agreement, pursuant to which Cynosure will acquire Palomar in a cash and stock transaction valued at approximately $294 million.

Commenting on the news, analyst Richard Newitter of Leerink Swann said "Ultimately we think it's a good strategic fit providing CYNO with a nexgen diode laser technology (Vectus), market-leading IPL platform (StarLuxe/Icon), and fractionated skin resurfacing (Emerge) --- all complementary areas to CYNO's current platform . . . and ultimately believe that PMTI's technologies will be better leveraged through CYNO's WW distribution and marketing machine going forward."

Leerink Swann has an Outperform rating on Cynosure (NASDAQ: CYNO).

For an analyst ratings summary and ratings history on Cynosure click here. For more ratings news on Cynosure click here.

Shares of Cynosure closed at $28.45 yesterday, with a 52 week range of $17.50-$30.20.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
• Goldman Positive on TransDigm (TDG) as Special Dividend Looms
• Wells Fargo Starts StealthGas (GASS) at Outperform

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?